Sun Pharma promoters lose Rs 126 bn in 10 days over insider trading charges
Shares plunge to a five-year low05-12-2018
05-12-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia04-12-2018
The unusual relationship between Sun Pharma and shareholder Aditya Medisales
Yesterday, Sun Pharma scrambled to quickly arrange a conference call and release clarifications on the recent accusations of insider trading against the company that have surfaced in the media, as well as rumors of a whistleblower complaint. Sun Pharma said that the allegations were either misinformation or misleading statements, and that these were either decades old, or inaccurate. However, the relationship between Aditya Medisales and Sun Pharma still remains unclear. Sun Pharma says that the current relationship between it and AMS was implemented to save taxes. Sun Pharma’s domestic formulations business is currently being routed through this company, which it calls a 'related party'. Aditya Medisales holds 1.67% in Sun Pharma shares, which is worth around Rs. 1,805 crores. It has held the same stake since at least December 2015, and it also holds shares in Sun Pharma Advanced Research. Sun disclosed financials of Aditya Medisales for FY18 as related party transactions, but didn't prior to that, explaining that the shareholding structure prior to FY18 was different. But the company has yet to clarify further, and Shanghvi says they may revise the relationship with AMS if it troubles investors. The questions on loans by Sun Pharma to AMS remain unanswered. Brokerage firm Macquarie's sales note highlights this, saying concerns remain on the way the business deal between Sun Pharma and Aditya Medisales was structured.04-12-2018
CLARIFICATION ON RECENT MEDIA REPORTS
We are pleased to enclose herewith our clarification related to recent media reports on Sun Pharma. This is for your information and record.03-12-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to USFDA Approval for Generic Ganirelix Acetate Injection, which we shall be releasing after sending this letter to you. This is for your information and record.03-12-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to 'Investor Update' call on December 03, 2018, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,03-12-2018
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Approval of Scheme of Arrangement among Sun Pharma Global FZE and Sun Pharmaceutical Industries Limited and their respective members and creditors for demerger of the Specified Undertaking of Sun Pharma Global FZE into the Company.01-12-2018
Insider trading returns to haunt Sun Pharma
Insider trading returns to haunt Sun PharmaSebi has powers to reopen cases of settlement related to insider trading on various grounds.01-12-2018
Sun Pharma: Governance issues, margin pressures expected to weigh on stock
Sun Pharma's outlook remains muted amid multiple negatives30-11-2018
Clarifies on news item
With reference to news appeared in "The Economic Times" dated November 29, 2018 quoting "Governance cloud over Sun Pharma", Sun Pharmaceutical Industries Ltd has submitted to BSE a copy of Clarification is enclosed.29-11-2018